Edesa Biotech, Inc.

172 articles with Edesa Biotech, Inc.

• Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study

  6/20/2019

  Edesa Biotech, Inc. reported that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which Edesa is developing as a potential treatment for chronic allergic contact dermatitis.

• Pardeep Nijhawan Acquires Common Shares of Stellar Biotechnologies, Inc.

  6/10/2019

  Following the completion of the Exchange, the Issuer changed its name to "Edesa Biotech, Inc." and Dr. Nijhawan was appointed as the Chief Executive Officer  and Secretary of the Issuer. 

• Edesa Biotech and Stellar Biotechnologies Complete Business Combination

  6/7/2019

   Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, today reported that the previously announced business combination with Stellar Biotechnologies, Inc. (Nasdaq: SBOT) ("Stellar"), which was completed pursuant to a share exchange agreement, has closed.

• Stellar Biotechnologies Reports Second Quarter Financial Results

  5/8/2019

  Stellar Biotechnologies, Inc. reported financial results for the three and six months ended March 31, 2019 and provided an update on its business.

• Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement

  3/8/2019

  Stellar Biotechnologies, Inc. has executed a share exchange agreement with privately-held Edesa Biotech Inc., a Canadian company, and Edesa's shareholders to create a company focused on the development of innovative therapeutics for dermatological and gastrointestinal indications with clear unmet medical needs.

• Stellar Biotechnologies Reports First Quarter Financial Results

  2/5/2019

  Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the three months ended December 31, 2018 and provided an update on its business.

• Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results

  11/30/2018

  LOS ANGELES,  /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the fiscal year ended September 30, 2018 and provided an update on its business

• Stellar Biotechnologies to Present at BlueTech Summit 2018

  10/31/2018

  Stellar Biotechnologies, Inc. announced today that Stellar President and CEO Frank R. Oakes will present at the 10th Annual BlueTech Summit to be held November 5-9, 2018 in San Diego, California.

• Stellar Biotechnologies to Supply KLH to National Institutes of Health

  9/5/2018

  Initiated product manufacturing for the NIH's National Cancer Institute, which plans to use a vialed formulation of Stellar KLH in dendritic cell-based cancer therapies.

• Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference

  8/28/2018

  20th Annual Global Investment Conference to be held September 4-6, 2018 in New York City.

• Stellar Biotechnologies Reports 2018 Third Quarter Financial Results

  8/8/2018

  Stellar Biotechnologies, Inc. reported financial results for the three and nine months ended June 30, 2018 and provided an update on its business.

• Stellar Issues Statement on Favorable Clinical Study Results

  7/5/2018

  Stellar Biotechnologies, Inc. issued a statement on the favorable Phase 2b study results published by Neovacs, S.A., a customer and joint venture partner.

• Stellar Achieves Robust Viral Clearance for Manufacturing Process

  5/24/2018

  This clearance step is a key quality assurance milestone under Stellar's initiatives to increase the scalability and throughput capacity of its manufacturing processes.

• Stellar Biotechnologies Announces Pricing of $5.5 Million Public Offering

  5/11/2018

  Stellar Biotechnologies is a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other disease

• Stellar Biotechnologies Announces One-for-Seven Reverse Split

  4/27/2018

  Stellar Biotechnologies, Inc. is announcing a one-for-seven reverse share split of its common shares.

• Stellar Biotech Begins Scale-Up and Expansion Project at Port Facility

  3/29/2018

  Stellar Biotechnologies, Inc. initiated the second phase of an expansion project at the Port of Hueneme, north of Los Angeles, California.

• Stellar Biotechnologies Appoints Bioprocess Expert to Lead Manufacturing

  2/27/2018

  Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, diabetes, lupus and cancers, among other diseases, today announced that Michael Kennedy has joined the company to lead the company's manufacturing activities.

• Stellar Biotechnologies Reports First Quarter 2018 Financial Results

  2/8/2018

  Stellar Chief Financial Officer Kathi Niffenegger said that during the first quarter, the company completed multiple engineering lots under its optimization initiative and continued to prioritize research and development.

• Stellar Biotechnologies Appoints Pharma Licensing Expert to Board of Directors

  1/25/2018

  Stellar Biotechnologies today announced the appointment of Deborah F. Aghib, Ph.D. to the company's Board of Directors.

• Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results

  12/1/2017

  During fiscal year 2017, the company advanced a number of strategic initiatives to optimize its manufacturing operations and to secure additional locations for the biologic source of KLH.